Rosiglitazone is a medicine used to help people with type 2 diabetes lower their blood sugar.
It belongs to a group of medicines called thiazolidinediones, which help the body respond better to insulin.
When it was first introduced, many experts hoped it would become an important treatment for diabetes.
Type 2 diabetes is a long-term condition in which the body cannot use insulin properly, causing blood sugar levels to rise.
If blood sugar stays too high for many years, it can damage the heart, kidneys, eyes, and nerves. Because of this, finding safe and effective medicines is very important.
A new study from the Yale School of Public Health has found that rosiglitazone may increase the risk of serious heart problems.
The researchers examined information from more than 130 clinical trials involving over 48,000 people, making it one of the largest and most detailed studies of the medicine.
The study, published in the BMJ, found that people taking rosiglitazone had a 33% higher risk of major cardiovascular events than people receiving other treatments or a placebo. These events included heart attacks, heart failure, and death related to heart disease.
Among 11,837 people taking rosiglitazone, 274 experienced a serious heart-related event. In the comparison group, 219 of 9,319 people had similar problems. Although the numbers may appear close, the overall increase in risk was considered important by the researchers.
Rosiglitazone was developed to improve blood sugar control, and it can be effective for that purpose. However, the new findings suggest that the possible benefits need to be carefully balanced against the increased risk to heart health.
The medicine has already faced restrictions in many parts of the world. It was suspended in Europe because of safety concerns, while its use in the United States has been tightly limited. These actions reflect growing concern about the medicine’s possible risks.
Previous studies did not always agree about how dangerous rosiglitazone might be. Some earlier research relied on limited information or different methods of analysis. The Yale team was able to study detailed patient-level data from many clinical trials, giving stronger evidence than many earlier reports.
The researchers also said that making clinical trial data available to independent scientists is very important. Open access to data allows experts to check results, confirm safety findings, and improve trust in medical research.
For people living with type 2 diabetes, the study is a reminder that lowering blood sugar is only one part of treatment. Doctors and patients should also think carefully about possible side effects, especially those that affect the heart.
The researchers said the goal is to find treatments that control diabetes well while keeping patients as safe as possible.
The study was published in the BMJ.
If you care about diabetes, please read studies about diabetes and vitamin B12, and the right diet for people with type 2 diabetes.
For more health information, please see recent studies about how to eat smart with diabetes, and turmeric and vitamin D: a duo for blood pressure control in diabetic patients.
Copyright © 2026 Knowridge Science Report. All rights reserved.
